GlassScriptPhysician profile
Alan Alvarado
NPI 1972581767
$2,936.91
in general payments reported to CMS, 2019-2025
27 companies · $433 in 2025
The $433 reported for 2025 was more than what 90% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $91.68 · 2021: $592 · 2022: $573 · 2023: $376 · 2024: $651 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.71 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $669.98 | 2021-2025 | Dupixent |
| Ironshore Pharmaceuticals INC. | $447.78 | 2019-2024 | Jornay Pm |
| Corium, LLC | $341.96 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $284.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $152.78 | 2021-2024 | Farxiga |
| Glaxosmithkline, LLC. | $139.64 | 2019-2025 | Nucala |
| Genzyme Corporation | $125.77 | 2024-2025 | |
| Sanofi Pasteur INC. | $108.96 | 2021-2025 | |
| Pfizer INC. | $104.53 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $93.21 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Csl Behring | $52.04 | 2022-2025 | Andembry, Haegarda |
| Nestle Healthcare Nutrition INC. | $36.62 | 2023 | |
| Seqirus USA INC | $33.98 | 2025 | Flucelvax |
| Shire North American Group INC | $27.96 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $25.18 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $22.10 | 2024 | Daybue |
| Ultragenyx Pharmaceutical INC. | $22.03 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.82 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $18.49 | 2022 | |
| Sobi, INC | $17.92 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.99 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $16.17 | 2023 | |
| Genentech USA, INC. | $16.16 | 2021 | |
| Dermavant Sciences, INC. | $14.67 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $13.91 | 2025 | |
| Alk-Abello, INC | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Alvarado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.